Navigation Links
Separating a cancer prevention drug from heart disease risk
Date:9/13/2011

Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?

Researchers at Winship Cancer Institute of Emory University have identified a way that celecoxib (Celebrex) pushes cancer cells into suicide, separately from its known effects. The Winship team's results outline a route to alternatives to celecoxib that keep its cancer-preventive properties while avoiding its risks.

Celecoxib's risk profile has confined its use to people who have inherited cancer risk or those who have had cancer already. Its effectiveness at stopping tumor progression and recurrence is being tested in several clinical trials for people who have had lung, head and neck and other types of cancer.

Shi-Yong Sun, PhD, and colleagues report in an upcoming issue of the journal Cancer Research that celecoxib inhibits an enzyme called GSK3 (glycogen synthase kinase 3) in lung cancer cells. This causes the disappearance of a protein called c-FLIP, which usually staves off apoptosis, a form of cellular suicide.

"We have been focusing on how celecoxib induces c-FLIP degradation and apoptosis in cancer cells, independent of COX-2 inhibition," Sun says.

Scientists think that celecoxib's ability to inhibit COX-2 enzymes is the basis for its anti-inflammatory properties as well as its influence on heart disease.

Sun is professor of hematology and medical oncology at Emory University School of Medicine and a Georgia Cancer Coalition Distinguished Cancer Scholar. The first author of the paper, postdoc Shuzhen Chen, is now at the Chinese Academy of Medical Sciences' Institute of Medicinal Biotechnology in Beijing. Fadlo Khuri, MD, deputy director of Winship Cancer Institute, is a co-author on the paper.

The result was surprising partly because until a few years ago, scientists thought that inhibiting GSK3, while possibly helpful in diseases such as diabetes, could promote cancer. However, recent results suggest that blocking GSK3 may stop cell growth in prostate, pancreatic and colon cancers and some types of leukemia.

Sun cautions: "We do not know whether GSK3 inhibition by celecoxib has anything to do with celecoxib's cardiovascular risk."


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related medicine news :

1. Web tool aims to improve the workplace for breast cancer survivors
2. IUD reduces the risk of cervical cancer
3. IUDs May Lower Womens Risk for Cervical Cancer: Study
4. Women With BRCA Mutations Get Cancer Diagnosis Earlier Than Before
5. NSAID Painkillers Linked to Risk of Kidney Cancer
6. X-ray protein probe leads to potential anticancer tactic
7. Lung cancer signatures in blood samples may aid in early detection
8. Women who inherit BRCA gene mutations develop cancer earlier than their ancestors
9. Breast cancer patients with BRCA gene diagnosed almost 8 years earlier than generation before
10. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
11. Talking -- or Not Talking -- Can Give Cancer Patients a Sense of Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Branches, Inc. is proud to ... Climb children and youth programs in South Miami. Macy’s is a wonderful community partner ... Grow Program provides afterschool tutoring, mentoring, enrichment and academic support to elementary students 5 ...
(Date:5/3/2016)... ... May 03, 2016 , ... Hydra Skin Sciences, a ... its Allegro Anti-aging Cream, a revolutionary new anti-aging skin care product that ... repair damaged skin, has sold over seventy-five thousand units worldwide within the first two ...
(Date:5/3/2016)... WA (PRWEB) , ... May 03, 2016 , ... Dave ... Pediatric Interim Care Center (PICC) annual fundraiser luncheon on Friday, May 20. ... that helps the smallest victims of drug abuse,” said Newberry. , PICC is a ...
(Date:5/2/2016)... , ... May 03, 2016 , ... ... its FDA approved sSOIP telemedicine stethoscope software that enables the stethoscope stream to ... called PCP-SSP and works with RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves ...
(Date:5/2/2016)... ... May 02, 2016 , ... ProElectric Cartoon is a package of 30 ... choose from a variety of electric styles including zap, sizzles, and more. Easily alter ... dof blur, three dimensional rotation, and much more. ProElectric Cartoon’s simplistic style makes it ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... India , April 29, 2016 ... Pipeline Review, H1 2016" market research report that ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:4/29/2016)... April 29, 2016 Glycotope GmbH, ... today announces the appointment of Dr. Alfredo Zurlo ... is an oncologist with many years clinical experience and ... industries. His last role was at Mologen AG where ... Executive Board. Previously Dr. Zurlo held various positions at ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
Breaking Medicine Technology: